Gan & Lee Pharmaceuticals.
603087
Rang in Aktien
#3011
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Aktienkurs
$10.03
Marktkapitalisierung
$5.99B
Veränderung (1 Tag)
-3.71%
Veränderung (1 Jahr)
2.30%
Land
CN
Handel Gan & Lee Pharmaceuticals. (603087)
Kategorie
Healthcare
P/S-Verhältnis für Gan & Lee Pharmaceuticals. (603087)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Gan & Lee Pharmaceuticals. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Gan & Lee Pharmaceuticals. von 2013 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2025 | 9.98 | 16.64% |
| 2024 | 8.56 | -25.20% |
| 2023 | 11.44 | 7.09% |
| 2022 | 10.68 | -2.29% |
| 2021 | 10.94 | -50.49% |
| 2020 | 22.08 | 74.82% |
| 2019 | 12.63 | -8.28% |
| 2018 | 13.77 | -0.87% |
| 2017 | 13.89 | -25.30% |
| 2016 | 18.60 | -31.05% |
| 2015 | 26.97 | -23.67% |
| 2014 | 35.34 | -20.02% |
| 2013 | 44.18 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 13.45 | - |
US
|
|
| 2.32 | - |
FR
|
|
| - | - |
JP
|
|
| 2.47 | - |
US
|
|
| - | - |
CH
|
